ANXA1 and COVID-19: The prognostic value of AnxA1 for COVID-19 was demonstrated by the observation that serum AnxA1 level was significantly lower in patients with severe or critical disease than in those with moderate disease or healthy control subjects, which is contrary to our findings; in the ROC curve analysis, the AUC for serum AnxA1 level in patients who needed ICU treatment was 0.701 (95% CI = 0.582–0.819; p = 0.003) with 69.8% sensitivity and 58.1% specificity at a cutoff of 17.2 ng/mL [12].